# Evaluating the Bioequivalence of HIP1302, HGP1406

> **NCT02545829** · PHASE1 · COMPLETED · sponsor: **Hanmi Pharmaceutical Company Limited** · enrollment: 38 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** HIP1302
- **DRUG:** HGP1406

## Key facts

- **NCT ID:** NCT02545829
- **Lead sponsor:** Hanmi Pharmaceutical Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08
- **Primary completion:** 2015-10
- **Final completion:** 2015-10
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2016-10-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02545829

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02545829, "Evaluating the Bioequivalence of HIP1302, HGP1406". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02545829. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*